Standard BioTools (NASDAQ:LAB) and WuXi AppTec (OTCMKTS:WUXIF) Head to Head Survey

Standard BioTools (NASDAQ:LAB) and WuXi AppTec (OTCMKTS:WUXIF) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations.

Institutional & Insider Ownership

53.7% of Standard BioTools shares are held by institutional investors. 26.8% of Standard BioTools shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Standard BioTools and WuXi AppTec”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$85.33 million	3.15	-$74.90 million	$0.22	3.11
WuXi AppTec	N/A	N/A	N/A	N/A	N/A

WuXi AppTec has lower revenue, but higher earnings than Standard BioTools.

Analyst Recommendations

This is a summary of recent recommendations for Standard BioTools and WuXi AppTec, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1	2	0	0	1.67
WuXi AppTec	0	0	0	0	0.00

Standard BioTools presently has a consensus price target of $1.35, indicating a potential upside of 97.22%. Given Standard BioTools’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Standard BioTools is more favorable than WuXi AppTec.

Profitability

This table compares Standard BioTools and WuXi AppTec’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Standard BioTools	100.36%	-7.57%	-6.14%
WuXi AppTec	N/A	N/A	N/A

Summary

Standard BioTools beats WuXi AppTec on 6 of the 8 factors compared between the two stocks.

About Standard BioTools

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

About WuXi AppTec

WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical testing services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.